Cytomegalovirus (CMV) is a ubiquitous herpesvirus that persists indefinitely after primary infection, usually in a latent form in various tissues (e.g., kidney, liver, lung). [1] One percent of ...

CMV is found in oropharyngeal secretions ... and chronic rejection in the form of bronchiolitis obliterans in lung transplant recipients, coronary atherosclerosis in heart transplant recipients ...

Cytomegalovirus (CMV) infection—which is thought to cause inflammation in atherosclerotic plaques—has been implicated in the development of vasculopathy in adult transplant recipients ...

More than 55% of transplant recipients with refractory CMV infections achieved confirmed ... locally advanced or metastatic non-small-cell lung cancer (NSCLC) patients whose tumours have EGFR ...

CMV is one of the most common and serious post-transplant infections with an estimated incidence rate of between 16% and 56% in solid organ transplants, and 30% to 70% in HSCT procedures.

Takeda (NYSE:TAK) said Chinese regulators have approved its drug Livtencity for the treatment of adults with post-transplant CMV disease. China’s National Medical Products Administration ...